Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 29, 2024 at 02:01 am EST
HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients an up to Once-Monthly Treatment...
United States Kristina Allikmets Demyelinating Polyneuropathy Research Development For Takeda Plasma Committee For Medicinal Products Human Use European Commission
Source: marketscreener.com